Data alert

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors1 and ß-blockers2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF). The results have translated into benefits in clinical practice, including reductions in death from HF.5 However, the prevalence of HF continues to increase. This may be a consequence of an aging population with high rates of hypertension and ischemic heart disease.6 Many of these patients have preserved LVEF, but all are at risk for hospitalization and cardiovascular (CV) death.

The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program included three parallel, independent, randomized, double-blind comparisons of the angiotensin-receptor blocker (ARB) candesartan with placebo. The trials tested whether candesartan would reduce mortality and morbidity in a broad range of patients with HF.7

References are listed at the end of the Data Alert.


Download 04DA_CHARM.ppt (7 slides - 1.4MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5 Slide 6 Slide 7
Data_Alert.pdf (1.5MB)Data_Alert.pdf (1.5MB)


Related at vwbg.org

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

New ACC/AHA Guidelines: Expanding the Role of Angiotensin Receptor Blockade in Heart Failure with LV Dysfunction

The 2005 ACC/AHA updated guidelines for the treatment of chronic HF and LV dysfunction in adults include an expanded role for ARBs as alternative therapy to ACEIs in selected patients and as added neurohormonal therapy in patients with persistent symptoms who are receiving optimal treatment.

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.
More related